Rango del día
$57.62 - $58.92
Cierre Anterior
$58.23
Rango de 52 semanas
$39.35 - $61.08
Volumen
7M
Capitalización de Mercado
$119.40B
Sector
Healthcare
Industry
Drug Manufacturers General
Country
US
Website
http://www.bms.com

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. The company's products include Opdivo for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, it offers Reyataz, a protease inhibitor to treat human immunodeficiency virus (HIV); Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. The company has collaboration agreements with Pfizer, Otsuka, Ono, Nektar, GRYT Health, Ubiquigent Limited, and Sensyne Health plc; clinical collaboration agreement with NeoImmuneTech, Inc.; partnership with Astrazeneca Plc.; and a discovery collaboration with Insitro, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Este contenido ha sido generado mediante un modelo de lenguaje de inteligencia artificial. Si bien nos esforzamos por lograr precisión y calidad, tenga en cuenta que es posible que la información proporcionada no esté completamente libre de errores o no esté actualizada. Recomendamos verificar de forma independiente el contenido y consultar con profesionales para obtener información específica. No asumimos ninguna responsabilidad por el uso o interpretación de este contenido. También tenga en cuenta que la información que se encuentra en la plataforma easyMarkets pretende ser únicamente informativa, no es un consejo ni una recomendación, ni una investigación, ni un registro de nuestros precios de negociación, ni una oferta o solicitud de una transacción en ningún instrumento financiero y por lo tanto no debe ser tratado como tal. La información proporcionada no involucra ningún objetivo de inversión específico, situación financiera ni necesidades de ninguna persona específica que pueda recibirla. Tenga en cuenta que el rendimiento pasado no es un indicador fiable del rendimiento y/o resultados futuros.